Neuropeptide Y promotes adipogenesis in chicken adipose cells in vitro.
Zhang W., Bai S., Liu D., Cline MA., Gilbert ER.
Animal Study, published in Comp Biochem Physiol A Mol Integr Physiol (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Comp Biochem Physiol A Mol Integr Physiol (2014)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 25461485
- DOI
- 10.1016/j.cbpa.2014.11.012
- Citations
- 33
Abstract (original English)
Neuropeptide Y is an evolutionarily conserved neurotransmitter that stimulates food intake in higher vertebrate species and promotes adipogenesis in mammals. The objective of this study was to determine if NPY also enhances adipogenesis in birds, using chickens as a model. The stromal-vascular fraction of cells was isolated from the abdominal fat of 14 day-old broiler chicks and effects of exogenous chicken NPY on proliferation and differentiation determined. Based on a thymidine analog incorporation assay and gene expression analysis, there was no effect of NPY on proliferation during the first 12 hours post-treatment in cells that were induced to proliferate. However, there were effects of NPY treatment on proliferation and lipid accumulation during the first 6 days post-induction of differentiation. Neuropeptide Y supplementation during induction of differentiation was associated with greater glycerol-3-phosphate dehydrogenase activity and staining for neutral lipids, indicative of augmented lipid accumulation. This was also accompanied by increased proliferation during differentiation, which was characterized by up-regulation of proliferation and preadipocyte marker mRNA, and a greater number of proliferating cells in groups that were treated with NPY. Additionally, NPY treatment was associated with increased expression of fatty acid binding protein 4 and lipoprotein lipase
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.